Lilly's second-quarter profits surge 16 percent

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s profits spiked 16 percent in the second quarter and the company raised its forecast for the rest of the year.

The Indianapolis-based drugmaker recorded profits of $1.3 billion, or $1.22 per share, during the three months ended June 30. Excluding a $27 million charge for severance payments to employees Lilly is laying off, the company’s earnings per share were $1.24.

On that basis, Wall Street analysts expected Lilly to earn just $1.10 per share, according to a survey by Thomson Financial Network.

Lilly’s revenue for the quarter rose 9 percent to $5.7 billion, also beating analysts’ expectations of $5.6 billion.

Sales growth in the quarter was led by Lilly’s lung cancer drug Alimta (up 43 percent), followed by its antidepressant Cymbalta (up 17 percent) and its anti-impotence pill Cialis (up 15 percent). Lilly’s bestseller, the antipsychotic Zyprexa, saw its sales rise 5 percent.

"Lilly continued to deliver solid financial results in the second quarter, driven by volume-based revenue gains and ongoing cost-containment efforts that resulted in double-digit earnings growth," Lilly CEO John Lechleiter said in a statement.

He added, “This strong financial performance enables us to fund our R&D pipeline of nearly 70 clinical stage assets and make strategic acquisitions in order to deliver an increased number of innovative medicines to patients in the future."

Lilly’s lack of new medicines to replace Zyprexa and Cymbalta, which will lose their patent protection in 2011 and 2013, respectively, has spooked investors. Lilly’s shares have essentially treaded water this year, falling 2 percent to $34.95 apiece.

Lilly no longer gives quarterly profit forecasts. But in April, it said it expected to earn $4.40 to $4.55 per share this year, excluding special items but including a 35-cent-per-share hit from the new health reform law.

Thursday, the company raised its forecast by a dime a share, to a range of $4.50 to $4.65, excluding special items.


  • Zyprexa profits
    Eli Lilly Zyprexa Claims Still Unresolved

    Eli Lilly Zyprexa can cause diabetes I took Zyprexa a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.

    This is a powerful drug that can damage a young person physiologically for life. Please take with caution and learn as much as you can about side effects. Eli Lilly's #1 cash cow Zyprexa drug sale $40 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

    Daniel Haszard Zyprexa whistle-blower

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ